Miguel A. Sanz

Fernando Abril Martorell Avenue, 106
Valencia, VC 46026, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 291 publications

Secondary Malignancies after Hematopoietic Stem Cell Transplantation.

Secondary Malignancies after Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: March 16, 2026

Secondary Malignancies After Hematopoietic Stem Cell Transplantation.

Secondary Malignancies After Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: March 16, 2026

Bone Marrow Transplantation From Matched and Mismatched Unrelated Donors With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia.

Bone Marrow Transplantation From Matched and Mismatched Unrelated Donors With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia.

Journal: Transplantation and cellular therapy

Published: November 12, 2025

Chronic graft-versus-host disease in the era of posttransplant cyclophosphamide.

Chronic graft-versus-host disease in the era of posttransplant cyclophosphamide.

Journal: Haematologica

Published: September 28, 2025

Clinicopathologic Features and Outcomes of Actinic Keratosis and Skin Cancer After Hematopoietic Stem Cell Transplantation.

Clinicopathologic Features and Outcomes of Actinic Keratosis and Skin Cancer After Hematopoietic Stem Cell Transplantation.

Journal: International journal of dermatology

Published: September 16, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Bacterial Bloodstream Infections After Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide.

Bacterial Bloodstream Infections After Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide.

Journal: Transplantation and cellular therapy

Published: August 08, 2025

Impact of busulfan- versus treosulfan-based conditioning on the incidence of sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation: a dual-center real-world study.

Impact of busulfan- versus treosulfan-based conditioning on the incidence of sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation: a dual-center real-world study.

Journal: Bone marrow transplantation

Published: August 03, 2025

Dicer is cleaved by the Leader protease encoded by foot-and-mouth disease virus to promote infection in mammalian cells.

Dicer is cleaved by the Leader protease encoded by foot-and-mouth disease virus to promote infection in mammalian cells.

Journal: Science advances

Published: July 04, 2025

Mold Invasive Fungal Infection in Hematopoietic Cell Transplant With Post-Transplant Cyclophosphamide and Posaconazole Prophylaxis.

Mold Invasive Fungal Infection in Hematopoietic Cell Transplant With Post-Transplant Cyclophosphamide and Posaconazole Prophylaxis.

Journal: Transplantation and cellular therapy

Published: May 26, 2025

Showing 1-12 of 291

Last Updated: 09/26/2026